Methods for treating conditions associated with MASP-2 dependent complement activation
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
1. A method for reducing the likelihood that a subject at risk for developing atypical hemolytic uremic syndrome (aHUS) will suffer clinical symptoms associated with aHUS comprising:
(a) determining the presence of a genetic marker known to be associated with aHUS in the subject;
(b) periodically monitoring the subject to determine the presence or absence of at least one symptom selected from the group consisting of anemia, thrombocytopenia, renal insufficiency and rising creatinine; and
(c) administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation upon the determination of the presence of at least one of anemia, thrombocytopenia, renal insufficiency or rising creatinine, wherein the composition is administered in an effective amount and for a sufficient time period to improve said one or more symptoms, wherein said MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody or fragment thereof that specifically binds to a portion of SEQ ID NO:6.
2. The method of claim 1 , wherein step (a) comprises performing a genetic screening test on a sample obtained from the subject and identifying the presence of at least one genetic marker associated with aHUS in a gene selected from the group consisting of complement factor H (CFH), factor I (CFI), factor B (CFB), membrane cofactor CD46, C3, complement factor H-related protein (CFHR1), anticoagulant protein thrombodulin (THBD), complement factor H-related protein 3 (CFHR3) and complement factor HI-related protein 4 (CFHR4).
3. The method of claim 1 , wherein the method further comprises monitoring the subject for the occurrence of an event known to be associated with triggering aHUS clinical symptoms and administering to the subject the composition comprising the MASP-2 inhibitory agent prior to, during, or after the occurrence of the triggering event.
4. The method of claim 3 , wherein the event associated with triggering aHUS clinical symptoms is selected from the group consisting of drug exposure, infection, malignancy, injury, organ or tissue transplant and pregnancy.
5. The method of claim 4 , wherein the infection is a bacterial infection.
6. The method of claim 3 , wherein the event associated with triggering aHUS clinical symptoms is drug exposure.
7. The method of claim 3 , wherein the event associated with triggering aHUS clinical symptoms is malignancy.
8. The method of claim 3 , wherein the event associated with triggering aHUS clinical symptoms is an organ or tissue transplant.
9. The method of claim 3 , wherein the event associated with triggering aHUS clinical symptoms is pregnancy.
10. The method of claim 1 , wherein the composition is administered subcutaneously.
11. The method of claim 1 , wherein the anti-MASP-2 antibody selectively inhibits MASP-2-dependent complement activation without substantially inhibiting the C1q-dependent complement pathway.
12. The method of claim 1 , wherein the MASP-2 inhibitory agent specifically binds to a polypeptide comprising SEQ ID NO:6 with an affinity of at least 10 times greater than it binds to a different polypeptide in the complement system.
13. The method of claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof is human or humanized.
14. The method of claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof is a recombinant antibody.